Roche Xenical (orlistat) reduces blood lipid levels by 10%; NDA filing before year-end.
Executive Summary
ROCHE XENICAL (ORLISTAT) REGIME PRODUCES 10% BLOOD LIPIDS DECREASE in some obese patients during a one-year Phase III study of the pancreatic lipase inhibitor, Roche Obesity Program/Clinical Science Leader Jonathan Hauptman, MD, reported at a "Pharma Research Press Day" Oct. 4 in Basle, Switzerland. Hauptman said patients with elevated low-density lipoprotein levels had a "very rapid and very good response" to Xenical, with about a 10% decrease in lipid levels compared to those patients on placebo, who experienced a "progressive increase" in levels after four weeks, with levels "moving up and down."